◎ResverlogixがASSURE臨床試験の患者募集完了

AsiaNet 50799

共同JBN 1241 （2012.9.27）

◎ResverlogixがASSURE臨床試験の患者募集完了

【カルガリー（カナダ・オンタリオ州）2012年9月26日＝共同JBN】Resverlogix Corp.（TSX:RVX）は26日、ハイリスクの心臓血管病患者を対象にした第2b相臨床試験「ASSURE」の患者募集を完了したと発表した。ASSUREはアテローム性動脈硬化症を後退させるResverlogixのBETタンパク質阻害剤、RVX-208の能力を冠状動脈疾患（CAD）患者で血管内超音波（IVUS）技術を使って、偽薬との比較で評価する。

Resverlogixのドナルド・マキャフリー社長兼最高経営責任者（CEO）は「ASSURE臨床試験の患者募集完了はアテローム性動脈硬化のプラーク減退においてRVX-208の効能を示すことを目標にしているResverlogixにとって新たな大きなマイルストーンである。RVX-208はApoA-Iの生成を刺激し、コレステロールを逆転送するのに必要な機能性HDL粒子を増加させる。ASSUREのトップラインのデータは2013年前半に発表できるとみている」と述べている。

ASSUREは26週間のマルチセンター、ダブルブラインド、無作為方式、比較グループ、偽薬対比の臨床試験で、クリーブランド・クリニックが指揮する。試験の主要エンドポイントはIVUSで測定したベースラインから26週までのアテロームの量的減少の測定である。ASSUREの副次目標はRVX-208の安全性と受容性の評価とHDLおよび非HDL脂質のパラメーターに対するRVX-208の効果の評価である。IVUSデータを使って、心筋梗塞のリスクに影響する重要な因子であるプラーク安定性の変化の評価も行う。

▽RVX-208について

RVX-208はBETブロモドメインを阻害するクラス初の小分子である。現在はアテローム性動脈硬化症の治療用に臨床研究が行われている。RVX-208は、アテローム性動脈硬化症のプラークを動脈外に運び出し、肝臓を通じて体外に排出する自然のプロセスであるコレステロールの逆転送（RCT）によってアテローム性動脈硬化症のプラークを除去する機能を持つ。RVX-208は機能性の高密度リポタンパク質（HDL）の重要な構成ブロックであり、RCTに必要なタイプであるApoA-Iの生成を増加させる。新たに生成されるので、これらの機能性HDL粒子は平らで空であり、効率的にプラークを除去してアテローム性動脈硬化症を安定または逆転させる。RVX-208は現在、第2b相研究でアテローム性動脈硬化症を逆転／安定させる能力の評価が行われている。この医薬品候補は神経退行性障害を含む他の症状の治療にも可能性がある。

▽Resverlogixについて

Resverlogix Corp.（TSX:RVX）は臨床段階の心臓血管病薬会社で、タンパク質生成を調節するエピジェネティック・プラットフォーム技術を持っている。Resverlogixはアテローム性動脈硬化症治療用のクラス初の小分子であるRVX-208を開発している。RVX-208は初のBETブロモドメイン阻害剤で、臨床試験段階にある。Resverlogixのエピジェネティック医薬品発見プラットフォームから生まれた新しい化合物はBETブロモドメインを阻害する機能を持ち、がん、自己免疫疾患、神経退行性障害を含む多くの病気に影響を及ぼす可能性がある。Resverlogixの公開株はトロント証券取引所で取引されている（TSX:RVX）。詳しい情報はhttp://www.resverlogix.comへ。

詳しい情報の問い合わせは以下へ。

企業問い合わせ先:

Donald J. McCaffrey

President and CEO

Resverlogix Corp.

Phone: 403-254-9252

Email: don@resverlogix.com

Sarah Zapotichny

Director of Investor Relations

Resverlogix Corp.

Phone: 403-254-9252

Email: sarah@resverlogix.com

米機関投資家問い合わせ先：

Susan Noonan

Managing Partner                  

S.A. Noonan Communications, LLC   

Phone: 212-966-3650               

Email: susan@sanoonan.com         

メディア問い合わせ先:

Matt Middleman, M.D.

Russo Partners, LLC

Phone: 212-845-4272

Email: matt.middleman@russopartnersllc.com

ソース：Resverlogix Corp.

Resverlogix Completes Enrollment In ASSURE Trial

PR50799

CALGARY, Ontario, Sept. 26, 2012 /PRN=KYODO JBN/ --

- IVUS data will evaluate plaque regression in patients with Coronary Artery

Disease

- TSX Exchange Symbol: RVX

Resverlogix Corp. (TSX:RVX) today announced that it has completed enrollment in

ASSURE, a Phase 2b clinical trial targeting high-risk cardiovascular disease

patients. ASSURE will evaluate the ability of RVX-208, Resverlogix's BET

protein inhibitor, to regress atherosclerotic disease versus placebo using

intravascular ultrasound (IVUS) technology in patients with coronary artery

disease (CAD).

"Completing enrollment of the ASSURE clinical trial marks another major

milestone for Resverlogix as we aim to demonstrate the efficacy of RVX-208 in

atherosclerotic plague regression," stated Donald McCaffrey, president and

chief executive officer of Resverlogix. "RVX-208 stimulates production of

ApoA-I, increasing the functional HDL particles required for reverse

cholesterol transport. We expect to announce top-line data from ASSURE in H1

2013."

ASSURE is a 26-week, multi-center, double-blind, randomized, parallel group,

placebo-controlled clinical trial led by the Cleveland Clinic. The primary

trial endpoint will be measurement of atheroma volume reduction from baseline

to 26 weeks measured by IVUS. Secondary objectives for ASSURE are evaluating

the safety and tolerability of RVX-208 and effects of RVX-208 on HDL and

non-HDL lipid parameters. Using IVUS data, we will also assess changes in

plaque stability, an important factor affecting risk of myocardial infarction.

About RVX-208

RVX-208 is a first-in-class, small molecule that inhibits BET bromodomains. It

is currently in clinical study for the treatment of atherosclerosis. RVX-208

functions by removing atherosclerotic plaque via reverse cholesterol transport

(RCT), the natural process through which atherosclerotic plaque is transported

out of the arteries and removed from the body by the liver. RVX-208 increases

production of ApoA-I, the key building block of functional high-density

lipoprotein (HDL) particles and the type required for RCT. Because they are

newly produced, these functional HDL particles are flat and empty and can

efficiently remove plaque and stabilize or reverse atherosclerotic disease.

RVX-208 is currently being evaluated in phase 2b studies for its ability to

reverse and/or stabilize atherosclerotic disease. The drug candidate also has

the potential to treat other indications, including neurodegenerative

disorders.

About Resverlogix

Resverlogix Corp. (TSX: RVX) is a clinical stage cardiovascular company with an

epigenetic platform technology that modulates protein production. Resverlogix

is developing RVX-208, a first-in-class small molecule for the treatment of

atherosclerosis. RVX-208 is the first BET bromodomain inhibitor in clinical

trials. New compounds arising from Resverlogix's epigenetic drug discovery

platform function by inhibiting BET bromodomains and have the potential to

impact multiple diseases including cancer, autoimmune and neurodegenerative

disorders. Resverlogix's common shares trade on the Toronto Stock Exchange

(TSX: RVX). For further information please visit http://www.resverlogix.com.

This news release may contain certain forward-looking information as defined

under applicable Canadian securities legislation, that are not based on

historical fact, including without limitation statements containing the words

"believes", "anticipates", "plans", "intends", "will", "should", "expects",

"continue", "estimate", "forecasts" and other similar expressions. In

particular, this news release includes forward looking information relating to

research and development activities and the potential role of RVX-208 in the

treatment of atherosclerosis. Our actual results, events or developments could

be materially different from those expressed or implied by these

forward-looking statements. We can give no assurance that any of the events or

expectations will occur or be realized. By their nature, forward-looking

statements are subject to numerous assumptions and risk factors including but

not limited to those associated with the success of research and development

programs, clinical trial programs including possible delays in patient

recruitment, the regulatory approval process, competition, securing and

maintaining corporate alliances, market acceptance of the Company's products,

the availability of government and insurance reimbursements for the Company's

products, the strength of intellectual property, financing capability, the

potential dilutive effects of any financing, reliance on subcontractors and key

personnel and additional assumptions and risk factors discussed in our Annual

Information Form and most recent MD&A which are incorporated herein by

reference and are available through SEDAR at http://www.sedar.com. The

forward-looking statements contained in this news release are expressly

qualified by this cautionary statement and are made as of the date hereof. The

Company disclaims any intention and has no obligation or responsibility, except

as required by law, to update or revise any forward-looking statements, whether

as a result of new information, future events or otherwise.

For further information, please contact:

Company Contacts:

Donald J. McCaffrey               Sarah Zapotichny

President and CEO                 Director of Investor Relations

Resverlogix Corp.                 Resverlogix Corp.

Phone: 403-254-9252               Phone: 403-254-9252

Email: don@resverlogix.com        Email: sarah@resverlogix.com

US Institutional Investors:       Media:

Susan Noonan

Managing Partner                  Matt Middleman, M.D.

S.A. Noonan Communications, LLC   Russo Partners, LLC

Phone: 212-966-3650               Phone: 212-845-4272

Email: susan@sanoonan.com         Email: matt.middleman@russopartnersllc.com

(RVX.)

SOURCE:  Resverlogix Corp.